[Conference Materials, Panel to Review GP-160 Vaccine Candidate (1992: Bethesda, Maryland)]

AFTER I DISCUSS THE CHARGE TO THE NIH, THE
COMMISSIONER OF THE FOOD AND DRUG
ADMINISTRATION, DR. DAVID KESSLER, WILL EXPLAIN
HIS AGENCY'S ROLE AS MANDATED BY THE RECENTLY
SIGNED DEPARTMENT OF DEFENSE APPROPRIATION (P.L.
102-396).
As THE LETTER THAT DR. MOSKOWITZ SENT YOU
EXPLAINS, THE DEPARTMENT OF DEFENSE
APPROPRIATION MANDATES THAT FEDERAL DOLLARS BE
SPENT TO LAUNCH A MAJOR EFFICACY TRIAL IN HIV
SEROPOSITIVE INDIVIDUALS OF A POTENTIAL AIDS
THERAPEUTIC VACCINE, GP-160. IT IS IMPORTANT
TO NOTE THAT THE CHARGE TO STUDY THIS PARTICULAR
VACCINE WAS NOT PLACED IN STATUTE BECAUSE GP-160
HAS PROVEN TO BE SUPERIOR TO OTHER CANDIDATE
VACCINES OR BECAUSE OF SOME OTHER COMPELLING
SCIENTIFIC OR MEDICAL IMPERATIVE. IT IS THE
SPECIFIC ROLE OF THIS PANEL -- OF ALL OF YOU

2